FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594476856> ?p ?o ?g. }

• W2594476856 abstract "Background:Aberrant signaling through HER2 and other members of the HER family has been identified as mediator of endocrine resistance in estrogen receptor alpha (ERα) positive breast cancer. On the other hand, ERα co-expression has been shown to attenuate the efficiency of anti-HER2 targeted therapies. These findings indicate that HER2 and ERα synergize to allow breast cancer cells to escape from both anti-ERα and anti-HER2-targeted therapies. Rationally designed clinical trials that combine endocrine therapy with anti-HER2 agents to interfere with HER2/ERα cross-talk have been conducted. However, the outcome of these trials suggests that novel therapeutic approaches are needed to further improve inhibition of HER2 and other HER family members in conjunction with a more efficient ERα blockade. We examined the ability of proteasome inhibitors (PIs) to disrupt HER2/ERα cross-talk in HER2+/ER+ breast cancer (BC) cells. Furthermore we investigated the potential of PIs to suppress the activity of a constitutively active HER2 variant resistant to trastuzumab and lapatinib. Methode: HER2+/ER+ BC cells and fulvestrant resistant ER+ BC cells that overexpress a constitutively active HER2 variant resistant to trastuzumab and lapatinib have been treated with the PIs carfilzomib and bortezomib. The potential of these PIs to suppress ERα expression, to block HER2 activation and to inhibit the HER2 downstream pathways PI3K/Akt and Ras/MAPK was monitored by western blotting. Induction of cell death upon PI treatment was measured by quantification of SubG1 cells using propidium iodide staining or the use of colony formation assays. Results: Carfilzomib and bortezomib markedly inhibit bi-directional HER2/ERα signaling pathways in HER2/ER+ BC cells. Both PIs suppress ERα expression, inhibit HER2 activity and subsequently suppress the HER2 downstream pathways PI3K/Akt and Ras/MAPK that are major executors for endocrine resistance. Furthermore we observed that both PIs stabilize the HER2 specific tyrosine phosphatase BDP1 (PTPN18), thereby suppressing the activity of even a constitutive active HER2 variant that cause resistance to trastuzumab and lapatinib. Based on these findings we hypothesize that PIs inhibits ERα and HER2 activity through different mechanisms as currently used therapeutic regiments. Conclusion: These findings demonstrate that PIs disrupt the cross-talk between HER2 and ERα signaling pathways and therefore might have the potential to expand treatment opportunities for HER2+/ER+ and possibly also for other groups of BC patients. Citation Format: Thaler S, Schmidt M, Thiede G, Schad A, Sleeman JP. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-12-14." @default.
• W2594476856 created "2017-03-16" @default.
• W2594476856 creator A5011248281 @default.
• W2594476856 creator A5042654448 @default.
• W2594476856 creator A5062682729 @default.
• W2594476856 creator A5066844833 @default.
• W2594476856 creator A5074656080 @default.
• W2594476856 date "2017-02-14" @default.
• W2594476856 modified "2023-09-27" @default.
• W2594476856 title "Abstract P6-12-14: Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells" @default.
• W2594476856 doi "https://doi.org/10.1158/1538-7445.sabcs16-p6-12-14" @default.
• W2594476856 hasPublicationYear "2017" @default.
• W2594476856 type Work @default.
• W2594476856 sameAs 2594476856 @default.
• W2594476856 citedByCount "0" @default.
• W2594476856 crossrefType "proceedings-article" @default.
• W2594476856 hasAuthorship W2594476856A5011248281 @default.
• W2594476856 hasAuthorship W2594476856A5042654448 @default.
• W2594476856 hasAuthorship W2594476856A5062682729 @default.
• W2594476856 hasAuthorship W2594476856A5066844833 @default.
• W2594476856 hasAuthorship W2594476856A5074656080 @default.
• W2594476856 hasConcept C121608353 @default.
• W2594476856 hasConcept C126322002 @default.
• W2594476856 hasConcept C2776364478 @default.
• W2594476856 hasConcept C2777329042 @default.
• W2594476856 hasConcept C2777478702 @default.
• W2594476856 hasConcept C2778367456 @default.
• W2594476856 hasConcept C2779786085 @default.
• W2594476856 hasConcept C2780482068 @default.
• W2594476856 hasConcept C502942594 @default.
• W2594476856 hasConcept C530470458 @default.
• W2594476856 hasConcept C71924100 @default.
• W2594476856 hasConcept C84606932 @default.
• W2594476856 hasConceptScore W2594476856C121608353 @default.
• W2594476856 hasConceptScore W2594476856C126322002 @default.
• W2594476856 hasConceptScore W2594476856C2776364478 @default.
• W2594476856 hasConceptScore W2594476856C2777329042 @default.
• W2594476856 hasConceptScore W2594476856C2777478702 @default.
• W2594476856 hasConceptScore W2594476856C2778367456 @default.
• W2594476856 hasConceptScore W2594476856C2779786085 @default.
• W2594476856 hasConceptScore W2594476856C2780482068 @default.
• W2594476856 hasConceptScore W2594476856C502942594 @default.
• W2594476856 hasConceptScore W2594476856C530470458 @default.
• W2594476856 hasConceptScore W2594476856C71924100 @default.
• W2594476856 hasConceptScore W2594476856C84606932 @default.
• W2594476856 hasLocation W25944768561 @default.
• W2594476856 hasOpenAccess W2594476856 @default.
• W2594476856 hasPrimaryLocation W25944768561 @default.
• W2594476856 hasRelatedWork W1544749943 @default.
• W2594476856 hasRelatedWork W1608985719 @default.
• W2594476856 hasRelatedWork W1983986257 @default.
• W2594476856 hasRelatedWork W1989116686 @default.
• W2594476856 hasRelatedWork W2033425661 @default.
• W2594476856 hasRelatedWork W2071865773 @default.
• W2594476856 hasRelatedWork W2080550759 @default.
• W2594476856 hasRelatedWork W2090237134 @default.
• W2594476856 hasRelatedWork W2092165713 @default.
• W2594476856 hasRelatedWork W2140202848 @default.
• W2594476856 hasRelatedWork W2221687828 @default.
• W2594476856 hasRelatedWork W2313077067 @default.
• W2594476856 hasRelatedWork W2323684834 @default.
• W2594476856 hasRelatedWork W2330720238 @default.
• W2594476856 hasRelatedWork W2565658677 @default.
• W2594476856 hasRelatedWork W2772424151 @default.
• W2594476856 hasRelatedWork W2793638865 @default.
• W2594476856 hasRelatedWork W2954998569 @default.
• W2594476856 hasRelatedWork W3037762932 @default.
• W2594476856 hasRelatedWork W3214371973 @default.
• W2594476856 isParatext "false" @default.
• W2594476856 isRetracted "false" @default.
• W2594476856 magId "2594476856" @default.
• W2594476856 workType "article" @default.